De Clerck F, Goossens J, Vermylen J, Hornstra G, Reneman R S
Arch Int Pharmacodyn Ther. 1976 Aug;222(2):233-42.
In rats, stasis thrombosis of a renal vein was produced by the occlusion of a vascular segment after induction of systemic hypercoagulability by i.v. injection of ellagic acid. Prostaglandin E1, at doses which reduced platelet retention by glass beads (6 mug/min/300 g i.v.) only slightly reduced the thrombus size. The platelet release inhibitors suprofen and indomethacin, at doses which prolonged tail bleeding time in rats (50 mg/kg i.v.) had no effect on the thrombus size. Heparin (10 and 20 U/kg i.v.) produced a marked, dose-related reduction of venous thrombosis. The platelet-active compound VK774, at the dose levels of 50 to 10 mg/kg i.v., also reduced the thrombus size to about half that of controls. Lower doses (5, 2.5 mg/kg i.v.) had a progressively weaker effect. Binding to ellagic acid or induction of coagulation changes by VK774 are proposed as possible mechanisms of action. It is concluded that, in comparison with the contribution of plasma coagulation, the participation of the aspects of platelet function we measured in the development of venous stasis thrombosis is comparatively small.
在大鼠中,通过静脉注射鞣花酸诱导全身高凝状态后,闭塞一段血管产生肾静脉淤滞性血栓形成。前列腺素E1,以能降低玻璃珠对血小板滞留作用的剂量(6微克/分钟/300克静脉注射)仅略微减小了血栓大小。血小板释放抑制剂舒洛芬和吲哚美辛,以能延长大鼠尾部出血时间的剂量(50毫克/千克静脉注射)对血栓大小没有影响。肝素(10和20单位/千克静脉注射)显著且呈剂量相关地减少了静脉血栓形成。血小板活性化合物VK774,以50至10毫克/千克静脉注射的剂量水平,也将血栓大小减小至对照组的约一半。较低剂量(5、2.5毫克/千克静脉注射)的作用逐渐减弱。VK774与鞣花酸结合或诱导凝血变化被认为是可能的作用机制。得出的结论是,与血浆凝血的作用相比,我们所测量的血小板功能方面在静脉淤滞性血栓形成发展中的参与相对较小。